Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis

Journal of Clinical Gastroenterology

Volumn 47, Issue 5, 2013, Pages 437-439

  Vahabnezhad, Elaheh ^a   Mochon, Albert Brian ^a   Wozniak, Laura Joyce ^a   Ziring, David Alexander ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

inflammatory bowel disease; Lactobacillus bacteremia; probiotics; ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; GENTAMICIN; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; PROBIOTIC AGENT; RIBOSOME RNA; RNA 16S; VANCOMYCIN;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; BLOOD CULTURE; BODY WEIGHT; BROTH DILUTION; CASE REPORT; CHILL; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; FECES LEVEL; FEVER; FLUSHING; HOSPITALIZATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LACTOBACILLUS RHAMNOSUS; MALE; OUTPATIENT CARE; PANCOLITIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RNA SEQUENCE; SEDIMENTATION RATE; SIDE EFFECT; SIGMOIDOSCOPY; TRAVELLER DIARRHEA; ULCERATIVE COLITIS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; COLITIS, ULCERATIVE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LACTOBACILLUS RHAMNOSUS; MALE; PROBIOTICS; RISK FACTORS; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA;

EID: 84876417481     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318279abf0     Document Type: Article

References (23)

1. Isenberg HD, D'Amato RF. Indigenous and pathogenic microorganisms of human. In: Murray PR, Baron EJ Pfaller MA, et al, eds. Manual of Clinical Microbiology. 6th ed. Washington, DC: ASM Press; 1995:5-18
2. Van Niel CW, Feudtner C, Garrison MM, et al. Lactobacillus therapy for acute infectious diarrhea in children: A metaanalysis. Pediatrics. 2002;109:678-684
3. Ringel Y, Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 2011;45:S145-S148
4. Reid G, Beuerman D, Heinemann C, et al. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol Med Microbiol. 2001;32:37-41
5. Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotic in primary prevention of atopic disease: A randomised placebocontrolled trial. Lancet. 2001;357:1076-1079
6. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebocontrolled trial. Gastroenterology. 2003;124:1202-1209
7. Wells JM. Immunomodulatory mechanisms of lactobacilli. Microb Cell Fact. 2011;10(suppl 1):S17
8. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1585-1596
9. Yoon SS, Sun J. Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. Gastroenterol Res Pract. 2011. [Epub ahead of print
10. Aguirre M, Collins MD. Lactic acid bacteria and human clinical infection. J Appl Bacteriol. 1993;75:95-107
11. Woo PCY, Ng KHL, Lau SKP, et al. Usefulness of the MicroSeq 500 16S ribosomal DNA-based bacterial identification system for identification of clinically significant bacterial isolates with ambiguous biochemical profiles. J Clin Microbiol. 2003;41:1996-2001
12. Struelens MJ. Consensus guidelines for appropriate use and evaluation of microbial epidemiologic typing systems. Clin Mircobiol Infect. 1996;2:2-11
13. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline, CLSI document M45-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2006
14. Land M, Rouster-Stevens K,Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;115:178-181
15. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis. 1999;28:1159-1160
16. Mackay AD, Taylor MB, Kibbler CC, et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect. 1999;5:290-292
17. Patel R, Cockerill FR, Porayko MK, et al. Lactobacillemia in liver transplant patients. Clin Infect Dis. 1994;18:207-212
18. Majcher-Peszynska J, Heine W, Richter I, et al. Persistent Lactobacillus casei subspecies rahmnosus bacteremia in 14 year old girl with acute myeloid leukemia. A case report. Clin Pediatr. 1999;211:53-56
19. Farina C, Arosio M, Mangia M, et al. Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol. 2001;33:251-252
20. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108
21. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-1546
22. Huynh HQ, Debruyn J, Guan L, et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. Inflamm Bowel Dis. 2009; 15:760-768
23. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437-443